FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to a cytotoxic antibody-drug conjugate comprising a cytotoxic substance attached to the N-terminal amino acid residue of the antibody heavy or light chain, wherein the cytotoxic agent is site-specifically attached to the N-terminal α-amino group of the native first amino acid residue of the antibody heavy or light chain, and the cytotoxic substance is attached to the antibody via a linker containing a reactive aldehyde group via a reductive alkylation reaction of said aldehyde group. Group of inventions also relates to a pharmaceutical composition for the treatment of a cancerous disease comprising said conjugate; a method of treating cancer comprising administering said conjugate.
EFFECT: group of inventions provides a reduction in the toxicity of the drug.
12 cl, 9 ex, 19 dwg, 16 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| MODIFIED ANTIBODIES LINKED WITH MOTIF INCLUDING CYSTEINE ??RESIDUE, CONJUGATES OF SAID MODIFIED ANTIBODY WITH DRUG SUBSTANCE AND METHODS OF PRODUCING SAME | 2013 |
|
RU2582259C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2787617C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| COMPOSITIONS AND METHODS RELATING TO DRUG CONJUGATES WITH ANTI-CD19 ANTIBODIES | 2019 |
|
RU2806333C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| LIGAND-CYTOTOXIC DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF | 2015 |
|
RU2685728C2 |
| MONOMETHYLVALINE COMPOUNDS CAPABLE OF FORMING CONJUGATES WITH LIGANDS | 2004 |
|
RU2448117C2 |
